(F) also, measuring the proportion of transfected cells by quantitating the flourescent marker protein contained in the cells harvested in (D);

A2 cncld.

(G) using FACS sorting to isolate single cells which deviate from an apoptosis background which is to be determined;

(H) isolating, amplifying and selecting the transfected plasmids in a further transfection process; and

(I) characterizing the corresponding genes on the plasmids isolated and amplified in (H) by sequencing and conducting expression and function studies.--

Remarks

Upon entry of the foregoing amendment, claims 19-45 are pending in the application, with claims 19, 26, 32, 41, and 45 being independent claims. Claims 1-18 are sought to be canceled without prejudice or disclaimer of the subject matter therein.

The amendment to the specification on page 11, line 12, replacing the word "new"with the "neu" does not add any new matter. The amendment is to correct a typographical error in the name of the receptor. The support for this change can be found in the title of the reference (# 32 listed on page 25 of the specification, Peles, E. and Yarden, Y. Bioessays 15: 815-24 (1993)) which refers to the gene - "Ne*u* and its ligands: from an oncogene to neural factors." (emphasis added) The abstract of this article states: "The neu gene (also called erbB-2 and

HER-2) encodes ... a receptor...." Therefore, the reference to a "new" gene is an obvious typographical error.

The amendment to the specification on page 14, line 6, in which after the words "For this purpose," the words "DNA coding for" are inserted, introduces no new matter. This phrase is supported on page 2 of the application, in which the method of the invention is described to include transient transfection of "a plasmid containing a DNA sequence of interest" (line 14-15) which corresponds to "*DNA coding for* a dominant-negative version of the human IGF-1 receptor. . . ." Additionally, the proposed phrase is inherent in the sentence and adds no new matter because a dominant-negative version of the human IGF-1 receptor could not be transiently transfected, while DNA coding for it could be.

The amendment to the specification on page 19, line 6, in which the words "and pulse width" after the first occurrence of the word "width" are deleted, does not add any new matter. This phrase is repeated in the sentence to be amended. Therefore the amendment is a correction of a typographical error and is obvious.

New claims 19-45 are sought to be added. Support for new claims 19-45 can be found in the original claims and throughout the specification. In particular, support for claim 19 can be found, *inter alia*, on page 2, lines 8-35, through page 3, lines 1-14, and also in original claim 1. Support for claim 20 can be found, *inter alia*, on page 6, lines 35-36, through page 7, lines 1-2, and also in original claim 2. Support for claim 21 can be found, *inter alia*, on page 4, lines 9-10, and also in original claim 3. Support for claim 22 can be found, *inter alia*, on page 5, lines 10-11, and also in original claim 4. Support for claim 23 can be found, *inter alia*, on page 5, line 11, and also in original claim 5. Support for claim 24 can be found, *inter alia*, on page 8, line 27-29, and also in original claim 8. Support for claim 25 can be found, *inter alia*, on page 4,

lines 20-22, and also in original claim 9. Support for claim 26 can be found, *inter alia*, in Examples 1, 2 and 3. Support for claim 27 can be found, *inter alia*, on page 11, lines 8-10, and page 13, lines 23-27 and in original claim 15. Support for claim 28 can be found on page 11, lines 8-10, and page 13, line 7, and also in original claim 15. Support for claim 29 can be found, *inter alia*, on page 11, line 10, and in original claim 16. Support for claim 30 can be found, *inter alia*, on page 11, line 10, and in original claim 17. Support for claim 31 can be found, *inter alia,* on page 11, line 11, and in original claim 18. Support for claim 32 can be found, *inter alia*, on page 10, lines 12-15, and in original claim 15. Support for claim 33 can be found, *inter alia*, on page 10, lines 12-15, page 13, lines 23-32, and in original claim 15. Support for claim 34 can be found on page 10, lines 12-15, page 13, lines 23-32, and in original claim 15. Support for claim 35 can be found, *inter alia*, on page 10, line 22, and in original claim 16. Support for claim 36 can be found, *inter alia*, on page 10, line 22, and in original claim 17. Support for claim 37 can be found, *inter alia,* on page 10, line 23, and in original claim 18. Support for claim 38 can be found, *inter alia*, on page 10, lines 15-17. Support for claim 39 can be found, *inter alia*, on page 10, lines 15-17. Support for claim 40 can be found, *inter alia*, on page 10, lines 15-17. Support for claim 41 can be found, *inter alia*, on page 16, lines 29-35 through page 17, lines 1-12, and in original claim 10. Support for claim 42 can be found, *inter alia*, on page 17, lines 14-16, and in original claim 11. Support for claim 43 can be found, *inter alia*, on page 4, lines 9-10, and in original claim 12. Support for claim 44 can be found *inter alia*, on page 8, lines 31-33, on page 18, lines 15-17, and in original claim 13. Support for claim 45 can be found on page 15, lines 6-22. These changes are believed to introduce no new matter, and their entry is respectfully requested.

It is not believed that extensions of time are required beyond those that may otherwise be provided for in accompanying documents. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Raz E. Fleshner
Attorney for Applicants
Registration No. 34,331

Date: August 2, 2000

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

P:\USERS\RAZF\0652\2080000\P97-58.wpd
SKGF Rev. 3/4/98